Children face much bigger health threats than polio. But immunization services for major childhood diseases such as diphtheria, tetanus and measles remain plagued with inefficiencies, poor oversight and a shortage of resources.

Full immunization rates for children in the country were last year estimated at 54% with wide variations across the country, compared to more than 95% in nearby Bangladesh. The figures for Pakistan may even be an overestimate: the survey excluded the FATA and vulnerable populations in mega-cities. In a household survey conducted this year, my colleagues and I found that 25% of children under five years in the urban slums of Karachi were not vaccinated for any childhood disease; the same was true for 64% of children in a relatively peaceful district of the FATA.

The time to act is now. The military offensive in North Waziristan has, paradoxically, opened up opportunities to provide health services to children from the FATA through care for displaced families. This could contribute to building community support and to re-establish the rule of law in conflict-ridden areas once people return. Ongoing support will be necessary to eradicate polio: children require multiple doses of vaccine to build immunity.

I fervently hope that the government and concerned agencies will devote their energies to scaling up full immunization efforts in these displaced and marginal populations, rather than diverting resources to international travellers. This is a chance to eradicate polio from the planet.

Zulfiqar Ahmed Bhutta is director of the Center of Excellence in Women and Child Health at the Aga Khan University in Karachi, Pakistan, and co-director of the Sick Kids Center for Global Child Health in Toronto, Canada. e-mail: zulfiqar.bhutta@aku.edu

- 1. Rutter, P. D. & Donaldson, L. J. *Lancet* **383**, 1695–1697 (2014).
- 1695–1697 (2014). 2. Mayer, B. T. et al. Am. J. Epidemiol. **177**, 1236–1245 (2013).
- 3. Blake, I. M. et al. Proc. Natl Acad. Sci. USA http://dx.doi.org/10.1073/ pnas.1323688111 (2014).
- İndependent Monitoring Board of the Global Polio Eradication Initiative Ninth Report — May 2014 (Global Polio Eradication Initiative, 2014).
- Bhutta, Z. A. Br. Med. J. 346, f280 (2013).
 Bhutta, Z. A. et al. Lancet 381, 2207–2218 (2013).
- National Institute of Population Studies and ICF International Pakistan Demographic and Health Survey 2012–13 (NIPS & ICF International, 2013).

The views expressed are those of the author alone, and do not necessarily reflect those of any institution with which he is affiliated. The author declares competing financial interests: see go.nature.com/cnhjcu for details.



A call for mentalhealth science

Clinicians and neuroscientists must work together to understand and improve psychological treatments, urge **Emily A. Holmes**, **Michelle G. Craske** and **Ann M. Graybiel**.

ow does one human talking to another, as occurs in psychological therapy, bring about changes in brain activity and cure or ease mental disorders? We don't really know. We need to.

Mental-health conditions, such as post-traumatic stress disorder (PTSD),

obsessive-compulsive disorder (OCD), eating disorders, schizophrenia and depression, affect one in four people worldwide. Depression is the third leading contributor to the global burden of disease, according to the World Health Organization. Psychological treatments have been subjected

For example, eating disorders were previously considered intractable within our

life time. They can now be addressed with a specific form of cognitive behavioural therapy (CBT)¹

"Neuroscientists and clinical scientists meet infrequently."

that targets attitudes to body shape and disturbances in eating habits. For depression, CBT can be as effective as antidepressant medication and provide benefits that are longer lasting². There is also evidence that interpersonal psychotherapy (IPT) is effective for treating depression.

A HOUSE DIVIDED

But evidence-based psychological treatments need improvement. Although the majority of patients benefit, only about half experience a clinically meaningful reduction in symptoms or full remission, at least for the most common conditions. For example, although response rates vary across studies, about 60% of individuals show significant improvement after CBT for OCD, but nearly 30% of those who begin therapy do not complete it³. And on average, more than 10% of those who have improved later relapse⁴. For some conditions, such as bipolar disorder, psychological treatments are not effective or are in their infancy.

Moreover, despite progress, we do not

yet fully understand how psychological therapies work — or when they don't. Neuroscience is shedding light on how to modulate emotion and memory, habit and fear learning. But psychological understanding and treatments have, as yet, profited much too little from such developments.

It is time to use science to advance the psychological, not just the pharmaceutical, treatment of those with mental-health problems. Great strides can and must be made by focusing on concerns that are common to fields from psychology, psychiatry and pharmacology to genetics and molecular biology, neurology, neuroscience, cognitive and social sciences, computer science, and mathematics. Molecular and theoretical scientists need to engage with the challenges that face the clinical scientists who develop and deliver psychological treatments, and who evaluate their outcomes. And clinicians need to get involved in experimental science. Patients, mental-health-care providers and researchers of all stripes stand to benefit.

Interdisciplinary communication is a problem. Neuroscientists and clinical scientists meet infrequently, rarely work together, read different journals, and know relatively little of each other's needs and discoveries. This culture gap in the field of mental health has widened as brain science has exploded. Researchers in different disciplines no longer work in the same building, let alone the same department, eroding communication. Separate career paths in neuroscience, clinical psychology and psychiatry put the fields in competition for scarce funding.

Part of the problem is that for many people, psychological treatments still conjure up

notions of couches and quasi-mystical experiences. That evidence-based psychological treatments target processes of learning, emotion regulation and habit formation is not clear to some neuroscientists and cell biologists. In our experience, many even challenge the idea of clinical psychology as a science and many are unaware of its evidence base. Equally, laboratory science can seem abstract and remote to clinicians working with patients with extreme emotional distress and behavioural dysfunction.

CHANGING ATTITUDES

Research on psychological treatments is, in the words of this journal, "scandalously under-supported" (see Nature 489, 473-474; 2012). Mental-health disorders account for more than 15% of the disease burden in developed countries, more than all forms of cancer. Yet it has been estimated that the proportion of research funds spent on mental health is as low as 7% in North America and 2% in the European Union.

Within those slender mental-health budgets, psychological treatments receive a small slice — in the United Kingdom less than 15% of the government and charity funding for mental-health research, and in the United States the share of National Institute of Mental Health funding is estimated to be similar. Further research on psychological treatments has no funding stream analogous to investment in the pharmaceutical industry.

This Cinderella status contributes to the fact that evidence-based psychological

treatments, such as CBT, IPT, behaviour therapy and family therapy, 🕏 have not yet fully benefitted from the range of dramatic advances have not yet fully benefitted from

in the neuroscience related to emotion, behaviour and cognition. Meanwhile, much of neuroscience is unaware of the potential of psychological treatments. Fixing this will require at least three steps.

CASE STUDY

Treating trauma with talk therapy

lan was filling his car with petrol and was caught in the cross-fire of an armed robbery. His daughter was severely injured. For the following decade lan suffered nightmares, intrusive memories, flashbacks of the trauma and was reluctant to drive — symptoms of post-traumatic stress disorder (PTSD).

lan had twelve 90-minute sessions of trauma-focused cognitive behavioural therapy, the treatment with the strongest evidence-base for PTSD, which brings about improvement in about 75% of cases. As part of his therapy, lan was asked to replay the traumatic memory vividly in his mind's eye. Ian also learned that by

avoiding reminders of the trauma his memories remained easily triggered, creating a vicious cycle. Treatment focused on breaking this cycle by bringing back to his mind perceptual, emotional and cognitive details of the trauma memory.

After three months of treatment, lan could remember the event without being overwhelmed with fear and guilt. The memory no longer flashed back involuntarily and his nightmares stopped. He began to drive again.

THREE STEPS

Uncover the mechanisms of existing psychological treatments. There is a very effective behavioural technique, for example, for phobias and anxiety disorders called exposure therapy. This protocol originated in the 1960s from the science of fear-extinction learning and involves designed experiences with feared stimuli. So an individual who fears that doorknobs are contaminated might be guided to handle doorknobs without performing their

compulsive cleansing rituals. They learn that the feared stimulus (the doorknob) is not as harmful as anticipated; their fears are extinguished by the repeated presence of the conditional stimulus (the doorknobs) without safety behaviours (washing the doorknobs, for example) and without the unconditional stimulus (fatal illness, for example) that was previously signalled by touching the doorknob.

But in OCD, for instance, nearly half of the people who undergo exposure ther-

apy do not benefit, and a significant minority relapse. One reason could be that extinction learning is fragile—vulnerable to factors such as failure to consolidate or generalize to new contexts, Increas-

"The amount spent on research into psychological treatments needs to be commensurate with their impact."

ingly, fear extinction is viewed⁵ as involving inhibitory pathways from a part of the brain called the ventromedial prefrontal cortex to the amygdala, regions of the brain involved in decision-making, suggesting molecular targets for extinction learning. For example, a team led by one of us (M.G.C.), a biobehavioural clinical scientist at the University of California, Los Angeles, is investigating the drug scopolamine (usually used for motion sickness and Parkinson's disease) to augment the generalization of extinction learning in exposure therapy across contexts. Others are trialling D-cycloserine (originally used as an antibiotic to treat tuberculosis) to enhance the response to exposure therapy⁶.

Another example illustrates the power of interdisciplinary research to explore cognitive mechanisms. CBT asserts that many clinical symptoms are produced and maintained by dysfunctional biases in how emotional information is selectively attended to, interpreted and then represented in memory. People who become so fearful and anxious about speaking to other people that they avoid eye contact and are unable to attend their children's school play or a job interview might notice only those people who seem to be looking at them strangely (negative attention bias), fuelling their anxiety about contact with others. A CBT therapist might ask a patient to practice attending to positive and benign faces, rather than negative ones.

In the past 15 years, researchers have discovered that computerized training can also modify cognitive biases⁷. For example, asking a patient (or a control participant) to repeatedly select the one smiling face from a crowd of frowning faces can induce a more positive attention bias. This approach enables researchers to do several things: test

the degree to which a given cognitive bias produces clinical symptoms; focus on how treatments change biases; and explore ways to boost therapeutic effects.

One of us (E.A.H.) has shown with colleagues that computerized cognitive bias modification alters activity in the lateral prefrontal cortex⁸, part of the brain system that controls attention. Stimulating neural activity in this region electrically augments the computer training. Such game-type tools offer the possibility of scalable, 'therapist-free' therapy.

Optimize psychological treatments and generate new ones. Neuroscience is providing unprecedented information about processes that can result in, or relieve, dysfunctional behaviour. Such work is probing the flexibility of memory storage, the degree to which emotions and memories can be dissociated, and the selective neural pathways that seem to be crucial for highly specialized aspects of the emotional landscape and can be switched on and off experimentally. These advances can be translated to the clinical sphere.

For example, neuroscientists (including A.M.G.) have now used optogenetics to block9 and produce10 compulsive behaviour such as excessive grooming by targeting different parts of the orbitofrontal cortex. The work was inspired by clinical observations that OCD symptoms, in part, reflect an over-reaction to conditioned stimuli in the environment (the doorknobs in the earlier example). These experiments suggest that a compulsion, such as excessive grooming, can be made or broken in seconds through targeted manipulation of brain activity. Such experiments, and related work turning on and off 'normal' habits with light that manipulates individual cells (optogenetics), raise the tantalizing possibility of optimizing behavioural techniques to activate the brain circuitry in question.

Forge links between clinical and laboratory researchers. We propose an umbrella discipline of mental-health science that joins behavioural and neuroscience approaches to problems including improving psychological treatments. Many efforts are already being made, but we need to galvanize the next generation of clinical scientists and neuroscientists to interact by creating career opportunities that enable them to experience advanced methods in both.

New funding from charities, the US National Institutes of Health and the European framework Horizon 2020 should strive to maximize links between fields. A positive step was the announcement in February by the US National Institute of Mental Health that it will fund only the psychotherapy

trials that seek to identify mechanisms.

Neuroscientists and clinical scientists could benefit enormously from national and international meetings. The psychological treatments conference convened by the mental-health charity MQ in London in December 2013 showed us that bringing these groups together can catalyse new ideas and opportunities for collaboration. (The editor-in-chief of this journal, Philip Campbell, is on the board of MQ.) Journals should welcome interdisciplinary efforts — their publication will make it easier for hiring committees, funders and philanthropists to appreciate the importance of such work.

WHAT NEXT

By the end of 2015, representatives of the leading clinical and neuroscience bodies should meet to hammer out the ten most pressing research questions for psychological treatments. This list should be disseminated to granting agencies, scientists, clinicians and the public internationally.

Mental-health charities can help by urging national funding bodies to reconsider the proportion of their investments in mental health relative to other diseases. The amount spent on research into psychological treatments needs to be commensurate with their impact. There is enormous promise here. Psychological treatments are a lifeline to so many — and could be to so many more.

Emily A. Holmes is at the Medical Research Council Cognition & Brain Sciences Unit, Cambridge, UK, and in the Department for Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Michelle G. Craske is in the Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA. Ann M. Graybiel is in the Department of Brain and Cognitive Sciences, McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

e-mail: emily.holmes@mrc-cbu.cam.ac.uk

- Fairburn, C. G. et al. Am. J. Psychiatry 166, 311–319 (2009).
- Hollon, S. D. et al. Arch. Gen. Psychiatry 62, 417–422 (2005).
- 3. Foa, E. B. et al. Am. J. Psychiatry **162**, 151–161 (2005).
- Simpson, H. B. et al. Depress. Anxiety 19, 225–233 (2004).
- Vervliet, B., Craske, M. G. & Hermans, D. Annu. Rev. Clin. Psychol. 9, 215–248 (2013).
- 6. Otto, M. W. et al. Biol. Psychiatry **67**, 365–370 (2010).
- MacLeod, C. & Mathews, A. Annu. Rev. Clin. Psychol. 8, 189–217 (2012).
- 8. Browning, M., Holmes, E. A., Murphy, S. E., Goodwin, G. M. & Harmer, C. J. *Biol. Psychiatry* **67**, 919–925 (2010).
- Burguière, E., Monteiro, P., Feng, G. & Graybiel, A. M. Science **340**, 1243–1246 (2013).
 Ahmari, S. E. et al. Science **340**, 1234–1239